✨ Free AI Report
Gracell Biotechnologies Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Gracell Biotechnologies Inc.
Company Research

Gracell Biotechnologies Inc.: Business Overview, Financials & Competitive Analysis

Gracell Biotechnologies is a clinical-stage biopharmaceutical company that primarily discovers and develops cell therapies for the treatment of cancer. The company leverages pioneering FasTCAR and TruUCAR technology p...

Analyst-debate audio for Gracell Biotechnologies Inc.

AskCyborg analysts argue the bull and bear cases for Gracell Biotechnologies Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
4/ 10Mixed

Cyborg Score thesis

Clinical-stage CAR-T innovator with potentially transformative manufacturing technology now backed by AstraZeneca's resources,...

Read the full analyst-debate transcript →
Industry Oncology Drugs
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Gracell Biotechnologies Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Gracell Biotechnologies Inc. Overview

Pro stress-test →

Gracell Biotechnologies is a clinical-stage biopharmaceutical company that primarily discovers and develops cell therapies for the treatment of cancer. The company leverages pioneering FasTCAR and TruUCAR technology platforms to create a robust clinical-stage pipeline of autologous and allogeneic product candidates, addressing significant challenges in conventional CAR-T therapies such as lengthy manufacturing times, suboptimal production quality, high costs, and lack of effective therapies for solid tumors.

Strategic Profile

Pro stress-test →

GC012F, an autologous CAR-T candidate utilizing the proprietary FasTCAR next-day manufacturing platform, has shown promise in treating multiple myeloma and other hematological cancers. The company was acquired by AstraZeneca, transitioning from independent clinical-stage developer to part of a major pharmaceutical conglomerate's oncology portfolio. As of July 2026, the company is in transition following its acquisition completion.

Competitive Landscape

Pro stress-test →

Gracell competes in the CAR-T immunotherapy space against established programs from Juno Therapeutics (Celgene/Bristol Myers Squibb), Gilead Sciences (Kite Pharma), CITIC Pharma (domestic competitor), and emerging allogeneic CAR-T developers. Its differentiation rests on FasTCAR next-day manufacturing and TruUCAR allogeneic platform, addressing speed and cost inefficiencies of conventional approaches. Post-AstraZeneca acquisition, competitive positioning shifts toward internal pipeline integration rather than standalone commercial development.

Industry Context

Gracell Biotechnologies Inc. operates in Oncology Drugs.

Key facts

Founded: 2017 · Headquarters: Suzhou, China · Employees: Unknown · Revenue: Pre-revenue clinical-stage company · Market cap: Approximately $990M as of February 2024 (pre-delisting); N/A post-acquisition

What the analysts stress-tested

The top findings that survived the multi-agent debate for Gracell Biotechnologies Inc..

  • As of May 2026, Gracell maintained approximately CNY 1.71 billion in cash reserves while carrying CNY 182.98 million in debt, indicating capital availability for continued pipeline development.
  • Lead programs GC012F (dual BCMA/CD19 CAR-T for multiple myeloma in Phase I), GC019F (CD19-directed CAR-T for B-ALL in Phase I), GC027 (CD7-directed allogeneic CAR-T in Phase I), and GC007g (CD19-directed allogeneic CAR-T in Phase 1/2) span both autologous and allogeneic modalities addressing hematologic malignancies.
+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2024Shareholders approved merger agreement with AstraZeneca and delisting from Nasdaq Global Select Market
  • May 2026Cash position of CNY 1.71 billion reported, indicating financial runway maintenance
  • +1 moreTrack every material event for Gracell Biotechnologies Inc. as it happens. Explore monitoring →
Get alerted when Gracell Biotechnologies Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Kite CAR-T therapiesEstablished CAR-T immunotherapy developer→KymriahCAR-T cell therapy for blood cancers and solid tumors→Allogene TherapeuticsAllogeneic CAR-T immunotherapy developer for oncology→CAR-T programsCell therapy company developing CAR-T and gene therapies→

Compare Gracell Biotechnologies Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Gracell Biotechnologies Inc. operates in Oncology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Drugs research →
NEW · MCP server

Ask your AI assistant about Gracell Biotechnologies Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Gracell Biotechnologies Inc. and its top competitor on Cyborg Score”
“What did Gracell Biotechnologies Inc. do this quarter?”
“Is Gracell Biotechnologies Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Gracell Biotechnologies Inc. do?+
Gracell Biotechnologies is a clinical-stage biopharmaceutical company that primarily discovers and develops cell therapies for the treatment of cancer. The company leverages pioneering FasTCAR and TruUCAR technology p...
What is Gracell Biotechnologies Inc.'s Cyborg Score?+
Gracell Biotechnologies Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Gracell Biotechnologies Inc.'s main competitors?+
Named competitors include Kite CAR-T therapies, Kymriah, Allogene Therapeutics, CAR-T programs. The full competitive landscape is in the AskCyborg report.
How can I get the full Gracell Biotechnologies Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Gracell Biotechnologies Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Gracell Biotechnologies Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.